A family of arginal thrombin inhibitors related to efegatran

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 2, 1996, Pages 173-183

  Smith, Gerald F ^a   Shuman, Robert T ^a   Craft, Trelia J ^a   Gifford, Donetta S ^a   Kurz, Kenneth D ^a   Jones, Noel D ^a   Chirgadze, Nickolay ^a   Hermann, Robert B ^a   Coffman, William J ^a   Sandusky, George E ^a   Roberts, Eiry ^a   Van Jackson, Charles ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antithrombin; Arginal; Efegatran; Thrombin; Thrombin inhibition

Indexed keywords

EFEGATRAN; LY 287045; LY 294291; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; PRIORITY JOURNAL; THROMBOPLASTIN TIME; THROMBOSIS;

EID: 8944231643     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999006     Document Type: Conference Paper

References (30)

1. Stein B, V Fuster, JL Halperin, JH Chesebro: Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. Circulation 80:1501-1513, 1989.
2. Bode W, D Turk, J Sturzebecher: Geometry of binding of the benzamidine- and arginine-based inhibitors NAPAP and MQPA to human alpha-thrombin. Eur J Biochem 193:175-182, 1990.
3. Kikumoto R, Y Tamao, T Tezuka, S Tononmura, H Hara, H Ninomiya, N Hijikata, S Okamoto: Selective inhibition of thrombin by (2R, 4R)-4-methyl-[N2-](3-methyl-1,2,3,4-tetrahydro-8-quinoyl)sulfonyl]-L-arginyl)2- piperidinecarboxylic acid. Biochemistry 23:85-90, 1984.
4. Bajusz S, E Szell, D Badgy, E Barabas, G Horvath, M Dioszegi, Z Fittler, G Szabo, A Juhasz, E Tomori, G Szilagyi: Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a tree tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative. J Med Chem 33:1729-1735, 1990.
5. Talbot M, J Ambler, KD Butler, VS Findlay, KA Mitchell, RF Peters, MF Tweed, RB Wallis: Recombinant desulfatohirudin CGP-39393 anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 61:77-80, 1989.
6. Maraganore JM, P Bourdon, J Jahlonski, KL Ramachandran, JW Fenton: Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29:7095-7101, 1990.
7. DiMaio J, B Gibbs, D Munn, J Lefebvre, F Ni, Y Konishi: Bifunctional thrombin inhibitors based on the sequence of hirudin 45-65. J Biol Chem 265:21698-21703, 1990.
8. Kettner C, L Mersinger, R Knabb: The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 265:18289-18297, 1990.
9. 2CI. Selective affinity label for thrombin. Thromb Res 14:969-973, 1974.
10. Shuman RT, RB Rothenberger, CS Campbell, GF Smith, DS Gifford-Moore, PD Gesellchen: Highly selective thrombin inhibitors. J Med Chem 36:314-319, 1992.
11. Blombäck B, B Hessel, D Hogg, G Claesson: Substrate specificity of thrombin on proteins and synthetic substrates. In: Lundblad RL (Ed): Chemistry and Biology of Thrombin. Ann Arbor Science, Ann Arbor. MI, 1977, pp 275-285.
12. Meinwald YC, RA Martinelli, JW van Nispen, HA Scheraga: Size of the Aα fibrinogen-like peptide that contacts the active site of thrombin. Biochemistry 19:3820-3830, 1980.
13. Shibata A: Diffraction data collection with R-axis II, an X-ray detecting system using maging plate. Rigaku J 7:28-32, 1990.
14. Chirgadze NY, D Clawson, PD Gesellchen, RB Hermann, RE Kaiser, JL Olkowski, DJ Sall, RW Schevitz, GF Smith, RT Shuman, JP Wery, ND Jones: The X-ray structure at 2.2 A resolution of a ternary complex containing human alpha-thrombin, a hirudin peptide (54-65) and an active site inhibitor. Presented at the annual meeting of the American Crystallographic Association, Pittsburgh, 1992.
15. Brunger AT: X-PLOR Version 3.1. A System for X-ray Crystallography and NMR. Yale University Press, New Haven, CT.
16. Hendrickson WA, JH Konnert: Restrained thermal factor refinement for macromolecules. In: Srinivasan R (Ed): Biomolecular Structure, Function, Conformation, and Evaluation. Vol 1. Pergamon, Oxford, 1981, pp 43-57.
17. Jones TA: FRODO: A graphics fitting program for macromolecules. In: Sayre D (Ed): Computational Crystallography. Clarendon, Oxford, UK, 1982, p 303.
18. Smith GF, BL Neubauer, JL Sundboom, K Best, RL Goode, LR Tanzer, RL Merriman, JD Frank, RG Herrmann: Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat. Thromb Res 150:163-174, 1988.
19. Smith GF, JL Sundboom, K Best, PD Gesellchen, RL Merriman, RT Shuman, BL Neubauer: Heparin, Boc-Phe-Pro-Arginal, and warfarin (fibrin antagonists) inhibit metastasis in an in vivo model. Biochem Abst Biol 70, 1987.
20. Williams JW, JF Morrison: The kinetics of reversible tight-binding inhibition. Methods Enzymol 63:437-467, 1979.
21. Bieth JG: Pathophysiological interpretation of kinetic constants of protease inhibitors. Bull Eur Pathophysiol Respirat 16:183-195, 1980.
22. Kurachi K, K Fujikawa, G Schmer, EW Davie: Inhibition of bovine factor IXa and factor Xaβ by antithrombin III. Biochemistry 15:373-377, 1976.
23. Davie EW, K Fujikawa, K Kurachi, W Kisiel: Role of serine proteases in the blood coagulation cascade. Adv Enzym Related Areas Mol Biol 48:277-318, 1979.
24. Jackson CV, JD Frank, VG Crowe, HC Wilson, WJ Coffman, BG Utterback, JA Jakubowski, GF Smith: Pharmacological assessment of the peptide thrombin inhibitor D-methyl-Phe-Pro-arginal (GYKI-14766) in a canine model of coronary thrombosis. J Pharmacol Exp Ther 261:546-552, 1992.
25. Wilson H, J Frank, V Crowe, W Coffman, GF Smith, R Shuman, CV Jackson: Anticoagulant and antithrombotic efficacy of the novel thrombin inhibitor D-methyl-Phg-Pro-arginal in a canine model of coronary thrombosis. Arteriosclerosis 11:1586A, 1991.
26. Jackson CV, HC Wilson, VG Crowe, RT Shuman, PD Gesellchen: Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: A comparison to heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol 21:587-594, 1993.
27. Smith GF, JL Sundboom: Heparin and protease inhibition. II. The role of heparin in the ATIII inactivation of thrombin, plasmin, and trypsin. Thromb Res 22:115-133, 1981.
28. Smith GF, RT Shuman, PD Gesellchen, TJ Craft, D Gifford, K Kurz, CV Jackson, GE Sandusky, P Williams: A new family of thrombin inhibitors with improved specificity and favorable therapeutic index. (Abst.) Circulation 84:11-579, 1991.
29. Jackson V, H Wilson, J Frank, V Crowe, W Coffman, T Craft, R Shuman, GF Smith: The novel thrombin inhibitor D-methyl-Phg-Pro-arginal: An effective conjunctive agent to coronary artery thrombolysis in the anesthetized dog. Arteriosclerosis 11:1586a, 1991.
30. Simoons M, T Lenderink, M Scheffer, I Stoel, P de Milliano, W Remme, H Werner, C Leeners, G Molloek, A Arnold, J Stibbe, E Roberts: Efegatran, a new direct thrombin inhibitor: Safety and dose response in patients with unstable angina. Circulation 90: I-231, 1994.